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ABSTRACT
Autologous stem cell transplantation is a curative procedure for many patients with lymphomas, and has been
shown to improve survival in patients with multiple myeloma. Approximately 20% of patients are unable to
mobilize sufficient hematopoietic stem cells to proceed safely to autologous stem cell transplantation. Para-
thyroid hormone (PTH) affects osteoblasts and the stem cell niche, and has been shown to improve survival
when given posttransplant in a mouse competitive transplant model. In this Phase I study, 20 subjects who had
1 or 2 unsuccessful stem cell mobilization attempts, received PTH in escalating doses of 40 g, 60 g, 80 g,
and 100 g for 14 days. On days 10-14 of treatment, subjects received filgrastim 10 g/kg. The PTH was
tolerated well and there was no dose-limiting toxicity. Forty-seven percent of subjects who had failed 1 prior
mobilization attempt met the mobilization criteria of >5 CD 34 cells/L in the peripheral blood. Forty
percent of subjects who failed to reach adequate CD34 cell counts in 2 prior mobilization attempts met the
mobilization criteria. PTH was well tolerated at doses up to 100 g in human cancer patients. The efficacy of
PTH for mobilization of hematopoietic stem cells will need to be tested in a larger Phase II study.
© 2007 American Society for Blood and Marrow Transplantation
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mNTRODUCTION
Chemotherapy followed by growth factor admin-
stration has become a standard strategy for mobiliza-
ion of peripheral blood stem cells (PBSCs) in prepa-
ation for autologous stem cell transplantation [1,2].
egardless of the mobilization strategy, approximately
0%-20% of patients fail to collect an adequate num-
er of stem cells to ensure engraftment [3,4]. Predic-
ive factors for poor mobilization have been studied
nd include age 70 years, 12 months of prior
herapy, and platelet count 200  109/L prior to
obilization [4]. Poor mobilization of PBSCs has also
een associated with worse transplant outcomes in
ymphoma patients [5].
Studies in mouse models have been undertaken to
ry to understand the stem cell niche, and thereby c
38ncrease stem cell numbers. Osteoblasts are a regula-
ory component of the hematopoietic stem cell niche
nd can be targeted as a means to increase stem cell
umbers [6,7]. Osteoblasts produce hematopoietic
rowth factors and are activated by parathyroid hor-
one (PTH) or the locally produced, PTH-related
rotein (PTH-rP), through the PTH/PTHrP recep-
or (PPR) [8,9]. The Notch signaling pathway regu-
ates cell fate in a wide variety of systems including
ematopoietic self-renewal [10]. Furthermore, the
otch ligand Jagged 1 is expressed by marrow stromal
ells and murine osteoblasts, and is increased with
PR activation [6]. It is one of several potential mo-
ecular mechanisms by which osteoblast stimulation
ay alter stem cell numbers [11,12].
Using either a genetic model where the PPR wasonstitutively active in osteoblasts or a pharmacologic
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Parathyroid Hormone and Stem Cell Mobilization 839odel where PTH(1-34) was used to activate PPR,
he Scadden laboratory has demonstrated a 2-fold
ncrease in hematopoietic stem cells in murine bone
arrow. This resulted in increased ability to engraft
rradiated recipient animals when either bone marrow
r granulocyte colony-stimulating factor (G-CSF)
obilized peripheral blood was used as a stem cell
ource. In addition, treatment of animals with PTH(1-
4) following transplantation with a limiting number
f stem cells markedly improved animal survival and
one marrow cellularity [6]. These data suggest that
sing PTH to alter activity of the stem cell microen-
ironment may improve either the yield of stem cells
erived from treated donors or the efﬁciency of en-
raftment in treated recipients. We hypothesized that
imilar activities may exist in humans and that PTH
ay provide a novel means of changing stem cell
umber and function in settings of clinical impor-
ance. The trial detailed here is our ﬁrst attempt to
est the safety of this approach in the context of stem
ell donors with cancer who have failed prior efforts at
tem cell mobilization.
We performed a Phase I study of PTH at 4 dif-
erent dose levels, given with ﬁlgrastim, to patients
ith hematologic malignancies who required a second
r third mobilization regimen.
ATIENTS AND METHODS
atients
Patients aged 18 to 75 years with relapsed or
efractory Hodgkin’s disease or non-Hodgkin’s lym-
homa, multiple myeloma, or acute myelogenous leu-
emia (AML) in second or subsequent remission or in
rst remission with high risk cytogenetics were eligi-
le for this study. Patients were eligible to participate
f they did not reach adequate CD34 cell counts in 1
r 2 prior mobilization attempts, deﬁned as 5
D34 cells/L in the blood or 2.0  106 CD 34
ells/kg after 4 apheresis collections. Patients with
erum calcium 10.5 mg/dL or a phosphate level
1.6 mg/dL were excluded. Patients also had to be
ligible for transplantation including ECOG perfor-
ance status of 0, 1, or 2, creatinine 2.0, bilirubin
2.0, ejection fraction 45%, and DLCO 50%
redicted. All subjects signed an informed consent
orm approved by the Institutional Review Boards of
ither M.D. Anderson Cancer Center or Dana Far-
er/Harvard Cancer Center.
reatment Plan
Treatment with PTH began within 21 days of
etermination that inadequate CD34 cells were ob-
ained in the prior mobilization regimen. All subjects
eceived human PTH(1-34) (teriparatide) given as a
ubcutaneous injection for days 1-14 of the study or cntil the completion of apheresis. PTH was supplied
n multidose pens; subjects were taught the appropri-
te use, and medication was given at home or in the
utpatient clinic, at the following dose levels: 40 g,
0 g, 80 g, and 100 g a day. Three subjects were
reated at each dose level, in ascending order, with an
dditional 3 subjects to be added for any dose limiting
oxicity. Subjects treated with more than 40 g a day
ad a daily dose escalation; for example, subjects
reated at the 100 g dose received 40 g on day 1, 60
g on day 2, 80 g on day 3, and then 100 g on days
-14. All subjects received ﬁlgrastim 10 g/kg daily on
ays 10-14 of the study or until the completion of
pheresis.
efinitions of Toxicity and Response
Calcium levels, phosphate level, ionized calcium,
lbumin, blood counts, and vital signs were monitored
hrice weekly. On the ﬁrst day of their maximal PTH
ose, subjects were monitored 4 hours after the PTH
ose as well. Dose-limiting toxicity was deﬁned as any
f the following: serum calcium level 11.5 mg/dL,
n ionized calcium level 1.5 mM, systolic blood
ressure 80 mmHg, phosphate 1.0 mg/dL. Mobi-
ization was deﬁned as a peripheral CD34 cell count
f 5 cells/L on day 14 of the study. Subjects who
et the mobilization criteria proceeded to stem cell
ollection and, if adequate numbers of stem cells were
ollected, autologous stem cell transplant. Subjects
ho did not meet the mobilization criteria were
reated off study.
tatistics
Time to neutrophil or platelet engraftment was
easured from day 0 of autologous stem cell trans-
lant and was estimated by the Kaplan-Meier method.
ne subject was censored at day 0 for platelet engraft-
ent as he did not nadir 20  109/L as a result of
ransfusion to maintain a platelet count 40  109/L
ecause of concomitant anticoagulation therapy.
ESULTS
atient Characteristics
Patient characteristics are outlined in Table 1.
wenty subjects were enrolled on this study. The
edian age was 57 years with a range of 24-71 years.
hirty-ﬁve percent of subjects were male. The major-
ty of subjects (85%) had lymphoma. Fifteen subjects
ad undergone 1 prior mobilization attempt and 5
ubjects had undergone 2 prior mobilization attempts.
ight subjects had received ﬁlgrastim mobilization
lone, and 12 subjects had received chemotherapy
lus ﬁlgrastim as their prestudy mobilization regimen.
rior mobilizations regimens included ﬁlgrastim alone,
yclophosphamide/ﬁlgrastim, rituximab/cyclophospha-
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K. K. Ballen et al.840ide/ﬁlgrastim, rituximab/ifosfamide/carboplatin/eto-
oside/ﬁlgrastim, and AMD3100/ﬁlgrastim. Eastern
ooperative Oncology Group Performance Status
as 0 for 13 subjects and 1 for 7 subjects.
oxicity and Dose Escalation
There was no dose-limiting toxicity at any of the 4
oses. Three subjects each were treated at the dose
evels of 40 g, 60 g, and 80 g. One subject in the
nitial 100 g cohort was admitted overnight with
ever and rigors, and therefore an additional 3 subjects
ere added at this dose level. This side effect did not
ccur again. Per protocol, an additional 5 subjects (for
total of 11) were enrolled at the highest dose. There
as no hypercalcemia (calcium 11.5 mg/dL) at any
ose level. The maximum calcium level was 11.3
g/dL and the maximum ionized calcium level was
.5 mM. Side effects experienced included 6 grade 3
oxicities as listed in Table 2.
The pre- and 4-hour post-PTH injection calcium
evels are outlined in Table 3.
obilization
Nine of the 20 subjects met the mobilization cri-
eria of5 CD34 cells/L on day14 of treatment.
he patients and their mobilizations results are dis-
layed in Table 4. The median peripheral blood
able 1. Patient Characteristics
Number of Patients
nstitution
Dana-Farber/Brigham & Women’s 7 (35%)
Massachusetts General Hospital 6 (30%)
MD Anderson Cancer Center 4 (20%)
Beth Israel Deaconess 3 (15%)
ge, years
Median 57
Range 24-71
ex
Male 7 (35%)
Female 13 (65%)
iagnosis
Non-Hodgkin’s lymphoma 12 (60%)
Hodgkin’s disease 6 (30%)
Multiple myeloma 2 (10%)
obilization prior attempts
1 15 (75%)
2 5 (25%)
able 2. Toxicities Related to PTH
Grade 3 Events Number of Subjects
eadache 2
uscle pain 1
ack pain 1
atigue 1p
ypothermia 1D34 count on day 14 was 3.3 cells/L, with a
ange of 0-20 cells/L. Seven of 15 subjects (47%)
ho had 1 prior unsuccessful mobilization attempt
et the mobilization criteria. Subjects who had pre-
iously received 2 unsuccessful mobilization regimens
id not fare worse; 2 of 5 subjects (40%) met the
obilization criteria. There did not appear to be an
ncreased mobilization efﬁciency at higher doses. Sub-
ects who did not achieve 5 CD 34 cells/l were
reated off study. Nine subjects went onto apheresis
nd required a median of 2 collections (range: 1-5) to
ollect a median of 1.5  106 CD34 cells/kg (range:
.1-3.0). Three subjects collected over 2 million
D34 cells/kg. However, of the 9 subjects evaluable
or apheresis collections, 2 subjects had access prob-
ems that limited success of apheresis and 1 patient’s
hysician elected to terminate collections prior to
ompletion because of a low initial stem cell yield.
arameters of Bone Activity
Osteocalcin and alkaline phosphatase (alk phos)
evels were not required as part of the protocol; how-
ver, pre- and posttreatment alk phos levels were
vailable on 8 subjects. The median pre treatment alk
hos was 137 U/L, with a range of 89-271. The
edian posttreatment alk phos was 195 U/L, with a
ange of 52-366. Five of these 8 patients met the
obilization criteria of 5 CD34 cells/l on day
14 of treatment. Four of these patients had an in-
rease in alk phos after PTH treatment ranging from
5 to 184 U/L, and 1 patient had a decrease in alk
hos of 76 U/L.
ransplantation Data
Six subjects proceeded to autologous stem cell
ransplant using PTH stimulated stem cell collections.
n 1 subject insufﬁcient CD34 cells were collected
nd 1 subject had an allogeneic transplant. Subjects
eceived a variety of conditioning regimens as appro-
riate for their disease. The median number of red
lood cell transfusions prior to engraftment was 4
range: 1-6) and the median number of platelet trans-
usions was 4 (range: 2-4). The median days to neu-
rophil engraftment, deﬁned as an absolute neutrophil
ount 0.5  109 cells/L was 11 days (range: 8-12
ays). The median days to platelet engraftment, de-
ned as a platelet count 20  109 cells/L unsup-
able 3. Calcium Levels before and after Parathyroid Hormone
njection
Maximum Calcium
(mg/dL)
Maximum Ionized
Calcium (mM)
reinjection 9.6 1.3
Hours Postinjection 10.1 1.4orted, was 19 days, with a range of 12-36 days. One
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Parathyroid Hormone and Stem Cell Mobilization 841ubject was transfused with platelets to maintain a
latelet count greater than 40 109 cells/L because of
oncomitant anticoagulation therapy. All 6 of these
atients are alive without evidence of disease, with a
edian follow up of 22 months (range: 20-26
onths).
ISCUSSION
In this phase I trial, we demonstrated that PTH
ould be administered safely to subjects as part of a
obilization strategy prior to autologous stem cell
ransplantation. We undertook these trials because in
pproximately 20% of patients who are candidates for
utologous stem cell transplant, insufﬁcient cells can
e collected to ensure rapid engraftment. The optimal
trategy to provide a suitable stem cell product for
hese patients is unclear. Options include remobiliza-
ion with growth factors with or without chemother-
py, bone marrow harvesting, proceeding to autolo-
ous stem cell transplantation with a low stem cell dose,
r allogeneic transplantation. Investigational agents,
uch as AMD3100, which inhibits the binding of stromal
erived growth factor-1 (SDF-1) or CXCL12 to its re-
eptor CXCR-4 are now in advanced clinical trials
13,14].
Studies of stem cell biology in mouse models led
o the discovery that the osteoblast is a component of
he regulatory stem cell niche, and that altering os-
eoblast activity by PPR stimulation could affect he-
atopoietic stem cell number and function [15]. This
as apparent in settings relevant for clinical transplan-
ation including stem cell harvesting and stem cell
able 4. Mobilization Characteristics
Patient
Number Age Disease
Num
Mo
1 48 Hodgkin’s
2 24 Lymphoma
3 36 Hodgkin’s
4 24 Hodgkin’s
5 58 Lymphoma
6 63 Lymphoma
7 55 Hodgkin’s
8 61 Lymphoma
9 26 Hodgkin’s
10 71 Lymphoma
11 61 Lymphoma
12 70 Lymphoma
13 68 Lymphoma
14 61 Myeloma
15 56 Myeloma
16 66 Lymphoma
17 50 Lymphoma
18 38 Hodgkin’s
19 35 Lymphoma
20 62 Lymphomangraftment. These ﬁndings suggested that manipu- lation of the stem cell niche could be a strategy for
mproving transplantation outcomes. Work by Jung
nd colleagues [16] suggested that PTH increases
tromal derived factor-1 (SDF-1) expression in the
one marrow, potentially contributing to homing.
owever, whether mouse models could predict hu-
an outcomes in this setting was unknown, and con-
ersion of the dose of hormone used in the mouse to
he human is complex with PTH because of the very
ifferent sensitivity of rodents to PTH. What was
nown from the mouse and could be anticipated in
umans, is that stimulation of osteoblasts was likely to
ake a prolonged interval prior to an appreciable effect
n the slowly cycling stem cells. In the mouse model
his interval was shown to be 28 days [6]. However, we
ere concerned that a prolonged interval of PTH
timulation would require modifying a standard ap-
roach to patients failing a prior mobilization and
xtend the time prior to their receiving potentially
urative intensive chemotherapy. We therefore chose
o restrict the interval of PTH dosing to 14 days,
hereby not subjecting the patient participants to a
elay in their chemotherapy, yet collecting important
afety data, but likely compromising our ability to
etect a biologic effect on stem cell number.
The doses chosen for study were based on prior
tudies of PTH as an anabolic agent to enhance bone
ineral density and reduce the risk of fracture [17,18].
arge-scale osteoporosis studies in men and post-
enopausal women have used doses of 20-40 g daily
f PTH(1-34) [19,20]. Side effects have included
eadaches, joint pain, muscle aches, and fatigue.
welve percent of women had an elevated calcium
Prior
ons PTH Dose
Peripheral Blood CD34
Count on Day 14
40 g 20.0
40 g 0
40 g 7.7
60 g 6.5
60 g 2.6
60 g 0
80 g 11.0
80 g 18.8
80 g 1.0
100 g 2.5
100 g 6.0
100 g 6.9
100 g 2.2
100 g 1.0
100 g 7.0
100 g 5.8
100 g 2.5
100 g 2.0
100 g 0.2
100 g 4.1ber of
bilizati
1
1
1
1
2
1
1
2
1
1
1
2
2
1
1
1
1
2
1evel; in 2% of women on long-term treatment the
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K. K. Ballen et al.842evel was above 11.2 mg/dL. In mouse studies,
TH(1-34) was shown to have a dose-related effect on
tem cell number [21]. Therefore, we performed a
ose escalation study, exceeding doses typically used
n treatment of osteoporosis by 5-fold. We found that
oses of PTH up to 100 g/day were tolerated well.
here was no dose-limiting toxicity and no serious
ypercalcemia. Mild headache and fever occurred in
nly 2 patients. No patient stopped PTH because of
oxicity. This may result from the vigorous prior treat-
ent of these patients potentially compromising their
steoclast function or simply from the short-term na-
ure of the trial. We would conclude, however, that
he dose of 100 g might be safely used for at least
hort intervals in further investigation of stem cell
ffects in patients with hematologic malignancies.
Peripheral blood CD34 cell concentration pre-
icts the CD34 yield in the leukapheresis product,
nd is used here as a marker of mobilization [22]. It is
ifﬁcult to determine whether PTH administration
nhanced CD34 cell collection, because other strat-
gies may result in similar outcomes and there was no
omparator group. For instance, ﬁlgrastim alone can
e used as a second mobilization strategy. In 1 study,
8% of patients obtained sufﬁcient cells (2.5  106
D34 cells/kg) to proceed to autologous stem cell
ransplant [23]. Filgrastim and sargramostim have also
een used together as a second mobilization strategy,
ith 50% of patients reaching the target goal of 3
illion CD34 cells/kg from the ﬁrst and second
obilization sessions [24]. A retrospective review
ompared PBSC harvesting to bone marrow harvest-
ng in patients who had failed to have 1 adequate stem
ell mobilzation [25]. Fifty-one percent of patients
ollected 2  106 CD 34 cells/kg from the second
obilization. In our study, the mobilization rate was
7% for second mobilizations and 40% for third mo-
ilizations, comparable to the reported literature.
owever, the study was not powered nor designed to
ddress efﬁcacy. All the patients that proceeded to
ransplant with PTH stimulated stem cells engrafted
ith a median day to absolute neutrophil count
ANC) of 500 of 11 days, similar to engraftment
eported in the literature after transplant with G-CSF
timulated stem cells [26]. There were no relapses in
his group of heavily pretreated patients, and all pa-
ients are alive and disease-free posttransplant. This
bservation in a limited number of patients is intrigu-
ng, as unpublished data suggests that rats treated with
aily PTH for 2 years had a dose-related decrease in
he development of spontaneous leukemia.
Further studies to address activity of PTH on stem
ells will require longer treatment intervals to test
hether it can enhance stem cell harvests. An alterna-
ive approach, however, would be to test whether
TH can improve the efﬁciency of stem cell engraft-
ent in recipients. A logical application using thispproach is umbilical cord blood transplantation. The
uccess rate of adult cord blood transplantation has
een limited by the low cell dose [27]. Strategies such
s double cord blood transplantation have been un-
ertaken to increase the cell dose, but time to cell
ount recovery is still prolonged, and infection, pre-
umably from poor immune reconstitution, remains
he primary cause of death [28,29]. A future study will
valuate PTH at the dose established here, 100 g a
ay, for 4 weeks following double cord blood trans-
lantation.
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